Skip to content

Supernus Pharmaceuticals SUPN Cash Flow Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$2.29M+80.6%-$4.11M-127%-$45.12M-217%$22.5M+13.0%-$11.83M-9,638%
$26.13M+28.2%$25.02M+32.7%$24.81M+23.4%$21.36M+3.1%$20.38M-1.8%
$8.48M+5.1%$9.65M+26.5%$7.83M+2.0%$7.51M+14.6%$8.07M+36.8%
$66.52M+117%$19.86M-55.3%$58.54M+64.3%$30.6M-20.3%
$0-100%$427K+100%$129K-35.5%$455K+611%$327K+31.9%
-$19.22M-151%$48.71M+163%$37.32M+172%
$9.12M+143%$8.53M+44.8%$21.07M+585%$935K-43.6%-$21.4M-1,463%
$56.42M+21.3%$8.11M+140%$28.86M+355%$46.52M+499%
$66.52M+120%$19.43M-56.0%$58.08M+63.3%$30.27M-20.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Supernus Pharmaceuticals generate?
Supernus Pharmaceuticals (SUPN) generated $175.5M in operating cash flow over the trailing twelve months.
What is Supernus Pharmaceuticals's free cash flow?
After $1.0M of capital expenditures, Supernus Pharmaceuticals's free cash flow was $174.3M over the trailing twelve months, up 1.8% year over year.
Where does Supernus Pharmaceuticals's cash flow data come from?
Every line is extracted from Supernus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.